January 14, 2021 -- Tonix Pharmaceuticals has filed a patent application for TNX-1500, a humanized monoclonal antibody (mAb) directed against the CD40-ligand, with the World Intellectual Property Organization.
If the claims are granted, a patent could potentially provide U.S. patent coverage for the TNX-1500 composition of matter through the year 2040, excluding possible patent term extensions or patent term adjustments.
The third-generation anti-CD40-ligand mAb was designed by protein engineering to decrease crystallizable fragment receptor (FcγRII) binding and the potential for thrombosis, while retaining efficacy, according to the company. TNX-1500 incorporates the antigen binding fragment (Fab) region of hu5c8, which has been extensively characterized, including at the atomic level in complex with the CD40-ligand.
The patent application includes claims related to proprietary anti-human CD40-ligand mAbs that were engineered to have modified effector functions, including TNX-1500, which have a reduced potential for Fc binding to FcγRII. It also claims uses of TNX-1500 for the prevention and treatment of conditions, such as organ transplant rejection and autoimmune disorders.
The company expects good manufacturing practice production of TNX-1500 to begin in the third quarter of 2021.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
